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Challenges in Drug Discovery for 
Neurofibromatosis Type 
1-Associated Low-Grade Glioma
Cora A. Ricker1†, Yuan Pan2†, David H. Gutmann2 and Charles Keller1*
1 Children’s Cancer Therapy Development Institute, Beaverton, OR, USA, 2 Washington University School of Medicine, 
St. Louis, MO, USA
Neurofibromatosis type 1 (NF1) is an autosomal dominant disorder that results from 
germline mutations of the NF1 gene, creating a predisposition to low-grade gliomas 
(LGGs; pilocytic astrocytoma) in young children. Insufficient data and resources repre-
sent major challenges to identifying the best possible drug therapies for children with 
this tumor. Herein, we summarize the currently available cell lines, genetically engineered 
mouse models, and therapeutic targets for these LGGs. Conspicuously absent are 
human tumor-derived cell lines or patient-derived xenograft models for NF1-LGG. New 
collaborative initiatives between patients and their families, research groups, and phar-
maceutical companies are needed to create transformative resources and broaden the 
knowledge base relevant to identifying cooperating genetic drivers and possible drug 
therapeutics for this common pediatric brain tumor.
Keywords: pilocytic astrocytoma, neurofibromatosis type 1, drug therapy, low-grade glioma, pediatric 
neuro-oncology
LAY SUMMARY
Neurofibromatosis type 1 (NF1) predisposes children to the low-grade glioma (LGG), pilocytic 
astrocytoma (PA). While these brain tumors are slow growing, the locations in which PAs arise 
make them difficult to surgically excise – often devastating to a child‘s sight or neurological function. 
Furthermore, no cell lines or xenograft models exist from which to develop new targeted therapies, 
leading to a sole reliance on transgenic models for mechanistic insights. Increased collaborations 
with affected patients and their families may hold the key to building the necessary resources to 
unravel biology and new therapies for this cancer.
iNTRODUCTiON
Low-grade gliomas account for 30% of primary pediatric central nervous system tumors, with PA 
predominating in children younger than 15 years of age (1). As a group, LGGs encompass both 
World Health Organization (WHO) grade I and II gliomas (2). Histologically, these tumors have 
low proliferative indices (<4%) with rare or absent mitotic figures and no evidence of necrosis. 
Abbreviations: cAMP, cyclic adenosine monophosphate; CSC, cancer stem cell; ERK, extracellular signal-regulated kinase; 
GAP, GTPase-activating protein; GEM, genetically engineered mice; GRD, GAP-related domain; HGG, high-grade glioma; 
iPSC, induced pluripotent stem cell; JNK, c-Jun-NH2-kinase; PA, pilocytic astrocytoma; LGG, low-grade glioma; MAPK, 
mitogen-activating protein kinase; MEK, mitogen-activated protein kinase kinase; mTOR, mechanistic target of rapamycin; 
NF1, neurofibromatosis type 1; NSCs, neural stem cells; PDX, patient-derived xenograft; PI3K, phosphoinositide 3-kinase; 
PKCγ, protein kinase C gamma; RAF, rapidly accelerated fibrosarcoma; RAS, rat sarcoma; RGC, retinal ganglion cells.
FiGURe 1 | MRi images of Neurofibromatosis type 1 (NF1)-associated 
low-grade glioma (LGG). LGGs (arrows) developing in children with NF1 at 
various locations, including optic nerves (A), asterisk indicates the chiasm, 
chiasm (B), thalamus (C), and brainstem (D). Arrows denote the location of 
the tumors.
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While distinguishing between these two malignancy grades 
can be challenging in some pediatric LGGs, PAs, unlike their 
WHO II counterparts, have characteristic eosinophilic granular 
bodies and Rosenthal fibers. In addition, PAs often contain a 
cystic component, especially when occurring in the cerebel-
lum, and frequently harbor areas of compacted bipolar cells 
alternating with loose-textured multipolar cells and microcysts. 
Many PAs may also enhance, especially in their peripheral rim 
if a cystic component exists. Enhancement does not denote 
high-grade glioma (HGG) in this case. Also, intense meningeal 
enhancement may occur in the absence of a cystic component. 
Cystic components do not usually exist in optic nerve gliomas, 
but do exist often in PAs. Similar to other glial malignancies, 
these pediatric LGGs are immunopositive for expression of glial 
fibrillary acidic protein (GFAP) and Olig2. Finally, these tumors 
harbor a rich extracellular matrix with prominent infiltration of 
monocytes.
In general, children with PA can be divided into distinct 
subgroups based on their molecular etiologies. First, the major-
ity of children with LGGs lack a genetic predisposition to brain 
cancer (sporadic PA). Pioneering genomic sequencing efforts by 
the Pfister laboratory and colleagues identified that the major-
ity of sporadic PA tumors are caused by a somatic genomic 
rearrangement of the KIAA1549 and BRAF genes to result in 
a fusion protein containing an unregulated and active BRAF 
kinase domain (3, 4). BRAFV600E mutations are most likely found 
in the extracerebellar and diencephalic regions (2). Subsequent 
studies revealed that this signature genomic alteration predomi-
nates in cerebellar and optic pathway PAs (5, 6). In addition to 
the KIAA1549:BRAF fusion, mutations in the fibroblast growth 
factor receptor 1 (FGFR1) and neurotrophic tyrosine kinase 
receptor 2 (NTRK2) genes are (more) common in non-cerebellar 
PAs (7).
The second group of children with PA includes those who har-
bor a germline mutation in the Neurofibromin (NF1) tumor sup-
pressor gene and, therefore, have NF1 as the genetic etiology for 
their brain tumors. Examination of these tumors reveals somatic 
loss of the remaining NF1 allele, resulting in bi-allelic NF1 inac-
tivation (8). Laboratory-based research over the past 20 years has 
revealed several potential opportunities for targeted inhibition of 
the growth control pathways deregulated in sporadic and NF1-
associated PAs. The NF1 gene encodes neurofibromin, a protein 
that primarily functions as a negative regulator of the RAS proto-
oncogene. In this regard, loss of NF1 gene expression leads to 
increased RAS activation and hyperactivation of the downstream 
RAS effectors, including the RAF/MEK/ERK and the PI3K/AKT 
(4) pathways, thereafter converging on the mechanistic target of 
rapamycin (mTOR) complex (9). Similarly, the KIAA1549:BRAF 
mutation results in increased MEK activation (10), which also 
operates to control cell growth through the mTOR complex (11). 
While less is known about the downstream signaling pathways 
operative in FGFR1- and NTRK2-mutant PAs, these receptor 
tyrosine kinase molecules are also known to activate RAS and 
RAS downstream signaling and regulate growth in numerous 
other cancers (12–16). These insights have resulted in the execu-
tion of early-phase clinical trials of MEK and mTOR inhibitors 
(NCT02285439 and NCT01734512; http://clinicaltrials.org), yet 
it is clear that additional resources and research will be required 
in order to develop personalized and effective therapies for these 
brain tumors.
Clinically, children with cerebellar PA come to medical atten-
tion when they present with signs and symptoms that reflect 
raised intracranial pressure, such as headaches, nausea/vomiting, 
blurred vision, and balance problems. Children with PAs involv-
ing the brainstem may exhibit reduced appetite, cranial neuropa-
thies, and drowsiness, while those with optic pathway gliomas 
(OPGs) may have reduced visual acuity or early-onset puberty 
when affecting the hypothalamus. For this reason, accurate age-
appropriate visual assessments are critical, especially for children 
with NF1, who are most at risk for the development of OPGs.
Therapeutically, individuals with sporadic PAs typically 
undergo surgical resection of the tumor, when feasible. This 
approach is most often employed for those tumors located within 
the cerebellum, but not for midline or optic pathway tumors. 
In these situations, chemotherapy (carboplatin/vincristine) is 
employed to halt further tumor growth. However, allergic reac-
tions have been reported from 2 to 30% of children with LGG 
(17). Risk of an allergic reaction from carboplatin and increased 
peripheral neuropathy from vincristine has led to vincristine 
being the first- or second-line monotherapy of choice (18–20). 
Since NF1-associated PAs are most commonly located in the optic 
pathway (optic nerve, chiasm, tracts, and radiations, Figure 1), 
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surgery is rarely performed, and most children with symptomatic 
tumors are treated with chemotherapy in the absence of a tissue 
diagnosis unless patients demonstrate atypical symptoms and a 
biopsy is deemed unnecessary. Alkylator-based chemotherapy 
is typically avoided due to the risk of treatment-induced malig-
nancy. Importantly, radiation therapy is rarely ever used due 
to the elevated risk of radiation-induced vasculopathy (21). 
With carboplatin/vincristine combination therapy, 56% (44/78) 
children with LGG exhibit an objective response, with two-year 
progression-free survival rates approaching 80% (22). In another 
study examining the combination of vincristine and carboplatin, 
52% (12/23) of children with recurrent LGG had an objective 
response, and seven of these children showed tumor reductions 
greater than 50% (23). Although outcomes are far from optimal, 
approximately one-third of patients who have received chemo-
therapy demonstrated improvement of vision (almost all being 
carboplatin-based within the study). These responses speak to 
the pressing need to develop targeted therapeutic agents for these 
tumors that inhibit the specific growth pathways deregulated in 
NF1-associated tumors.
A total of 15–20% of children with NF1 develop LGGs 
(24–26), affecting 1:2,500 individuals worldwide. Over two-
thirds of these PAs arise in the optic pathway (optic nerves, 
chiasm, tracts, and radiations), with another 15% located in the 
brainstem (27). Although rare, NF1 is one of the most common 
genetic disorders in humans, and PAs, when included in the 
LGG category, are the most common pediatric brain tumors. 
Thus, developing therapies for NF1-associated PAs could have a 
major impact on LGGs.
CURReNT eNABLiNG ReSOURCeS
Patient Registries and Biobanks
Patient registries provide important information regarding 
demographic and clinical characteristics. Currently, there are 
several registries for brain tumors and others, specifically for 
NF1. Dr. Michael Fisher at the Children‘s Hospital of Philadelphia 
leads a large international study group for NF1-OPG aimed at 
defining the natural history and outcomes for these tumors. In 
2012, the Children‘s Tumor Foundation (CTF) created the NF 
Registry. The NF Registry is a tissue repository managed by 
Precision Bioservices and curated by Patients Crossroads Inc. 
The NF registry notifies patients of new clinical trials and pos-
sible treatments, allows patients to compare medical histories, 
and enables patients to connect with researchers on pressing 
issues.
Additionally, the Washington University Neurofibromatosis 
(NF) Center created (May 2011) and currently hosts the 
Neurofibromatosis Type 1 (NF1) Patient Registry Initiative (28). 
This epidemiologic database serves a different purpose than the 
CTF Registry. It was specifically designed to facilitate clinical 
association studies that can be mechanistically explored in the 
laboratory. As such, this registry has been invaluable for assessing 
how internet-based epidemiological research can be optimally 
conducted (29, 30) and for identifying unanticipated associa-
tions between specific clinical features for future risk assessment 
analysis (31–33).
Although not specific to NF1, the National Cancer Data Base 
is a program established by the American College of Surgeons 
in collaboration with the American Cancer Society to provide 
oncology results from Commission on Cancer (CoC)-accredited 
hospital registries. In addition, the Central Brain Tumor Registry 
of the United States provides an invaluable resource for descrip-
tive statistical data on all primary tumors, while the Swedish 
Cancer Registry houses similar data on LGG and HGG (34). 
Several other cancer registries, which track LGGs from around 
the world, are summarized in Table 1.
Finally, a number of institutions and laboratories, in close 
collaboration with neurosurgical teams, are pioneering the crea-
tion of LGG tumor banks. For example, the Pediatric Low-Grade 
Astrocytoma Program at the Dana Farber Cancer Institute has 
invested in a tissue banking research effort to abstract data of each 
tumor and distribute the frozen tissue to investigators. Similar 
biospecimen repositories also exist at Johns Hopkins University, 
St. Louis Children‘s Hospital/Washington University, Children‘s 
National Medical Center, and St. Jude Children‘s Research 
Hospital. Nevertheless, the general lack of frozen tissue samples 
has hindered comprehensive analyses of cooperating molecular 
changes in NF1-associated PA. The lack of surgical specimens 
reflects the current practice of treating these tumors without a 
tissue diagnosis because current clinical practices exclude giving 
patients a biopsy unless they present clear abnormal clinical or 
radiological symptoms. However, by pooling these rare biopsy 
materials from a large number of institutions, programs like 
the NF1 Synodos LGG Initiative, spearheaded by the Children‘s 
Tumor Foundation, aim to perform comprehensive genetic and 
genomic sequencing of these tumors.
Cell Lines
Cell lines are typically derived from patients or animal models. 
Establishing cell lines from patient tumors would be ideal for test-
ing preclinical drugs because these lines closely resemble actual 
human tumors and may more closely mirror the response of a 
particular patient‘s tumor to treatment. Unfortunately, despite 
efforts by many research groups, human NF1-PA cell cultures 
have yet to be successfully established. It is not clear whether this 
reflects issues with cellular senescence or the need for trophic 
growth factors from the normal microenvironment. As such, 
continual passage of sporadic tumors is associated with loss of 
the signature fusion BRAF alteration (KIAA1549:BRAF) and 
oncogene-induced senescence (35). To date, only a small num-
ber of PA cell lines and their genetic characteristics have been 
reported, which are summarized in Table 2, including NCH492 
(BRAF duplication (4)), IPNT-H (36), and Res186 (PTEN dele-
tion and TP73 promoter hypermethylation (37, 38)). However, 
none of the LGG cell lines have reported NF1 gene loss/mutation. 
Further characterization of the existing sporadic LGG cell lines as 
well as the development of NF1-LGG cell lines are needed.
At the Washington University NF Center, investigators 
launched the NF1 Brain Trust Project in October 2012 to create 
a repository of NF1 patient-induced pluripotent stem cell (iPSC) 
lines. While these are not glioma cells, they provide a renewable 
source of human cells for cellular reprograming. Importantly, 
these iPSC lines were instrumental in demonstrating that 
TABLe 1 | international Cancer Registries for Low-Grade Astrocytoma.
Cancer registry Location
French Registry of Children Solid Tumors https://epidemiologie-france.aviesan.fr/fr/epidemiologie-france/accueil France
STEP Registry: Registry for rare tumors in children and adolescents http://www.klinikumdo.de/fs1/medizin/kliniken-und-abteilungen/
klinik-fuer-kinder-und-jugendmedizin/ 
Germany
Austrian Cancer Registry http://www.statistik.at/web_de/statistiken/index.html Austria
Estonian Cancer Registry http://www.tai.ee/en/r-and-d/registers/estonian-cancer-registry Estonia
Suomen Syöpärekisteri (Finnish Cancer Registry) http://www.cancer.fi/syoparekisteri/en/ Finland
Epidemiological Cancer Registry Baden-Württemberg http://www.dkfz.de/de/krebsregister/index.html Germany
Bayern Population Based Cancer Registry Germany
MCR—Munich Cancer Registry http://www.tumorregister-muenchen.de/ Germany
Common Cancer Registry of Berlin, Brandenburg, Mecklenburg-Western Pomerania, Saxony-Anhalt, and the free states Saxony and Thuringia http://
www.berlin.de/gkr/ 
Germany
Bremen Cancer Registry http://www.krebsregister.bremen.de/home.html Germany
Hamburg Cancer Registry http://www.hamburg.de/krebsregister/ Germany
German Childhood Cancer Registry (Partner of ACCIS: Automated Childhood Cancer Information System) http://www.kinderkrebsregister.de/dkkr/
ueber-uns/uebersicht.html 
Germany
EKRS: Saarland Cancer Registry http://www.krebsregister.saarland.de/ Germany
German Central Children Tumor Registry http://www.patho.uni-kiel.de/ Germany
Schleswig-Holstein Cancer Registry http://www.krebsregister-sh.de/ Germany
Icelander Cancer Registry http://www.krabbameinsskra.is/indexen.jsp?id=b Iceland
Maltese Cancer Registry http://ehealth.gov.mt/HealthPortal/strategy_policy/healthinfor_research/registries/cancers.aspx Malta
Norwegian Cancer Registry https://www.kreftregisteret.no/en/ Norway
Kielce Cancer Registry https://www.onkol.kielce.pl/pl/onkol?destination=onkol Poland
Cracow Cancer Registry http://www.orpha.net/consor/cgi-bin/ResearchTrials_RegistriesMaterials.php?lng=EN&data_id=76337&RegistryMat
erialName=Mazowiecki-Rejestr-Nowotworow-nalezacy-do-projktu-RARECARE&title=Mazowiecki-Rejestr-Nowotworow-nalezacy-do-projktu-
RARECARE&search=ResearchTrials_RegistriesMaterials_Simple
Poland
Mazovian Cancer Registry http://www.orpha.net/consor/cgi-bin/ResearchTrials_RegistriesMaterials.php?lng=EN&data_id=76337&RegistryMa
terialName=Mazowiecki-Rejestr-Nowotworow-nalezacy-do-projktu-RARECARE&title=Mazowiecki-Rejestr-Nowotworow-nalezacy-do-projktu-
RARECARE&search=ResearchTrials_RegistriesMaterials_Simple
Poland
Registo Oncológico Regional Sul http://www.ror-sul.org.pt/pt Portugal
National Cancer Registry http://www.nczisk.sk/en/Pages/default.aspx Slovakia
Slovenian Cancer Registry http://www.onko-i.si/ Slovenia
Swedish Childhood Cancer Registry http://ki.se/en/kbh/paediatric-oncology Sweden
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different germline NF1 gene mutations result in different levels 
of neurofibromin expression (39). Current work is underway to 
use these lines as cellular substrates for glioma modeling, as part 
of the CTF NF1 Synodos Initiative.
Genetically engineered Mouse Models
In the absence of patient-derived cell lines or xenografts, geneti-
cally engineered mice (GEM), listed in Table  3, have emerged 
as instructive models for elucidating the cellular and molecular 
determinants critical for glioma formation and growth. While 
mice with a germline Nf1 gene mutation (Nf1+/− mice) do not 
develop gliomas, neither do mice in which both copies of the Nf1 
gene are inactivated in neuroglial progenitors (40), suggesting 
that bi-allelic Nf1 gene inactivation in the proper cell of origin is 
not sufficient for glioma formation. To better model NF1-PA aris-
ing in children with a germline NF1 gene mutation, Nf1+/− mice 
were generated in which somatic loss of the remaining functional 
Nf1 allele occurs in neuroglial progenitors (40–42). Analysis of 
the resulting mice revealed that gliomas arise between 10 and 
12  weeks of age in the prechiasmatic optic nerves and chiasm 
with >90% penetrance. While these LGGs lack the characteristic 
eosinophilic granule bodies and Rosenthal fibers commonly 
found in NF1-PA, the murine optic glioma tumors share several 
similarities with their human counterparts. These tumors display 
frank tissue distortion evident on MRI, low proliferative indices, 
increased microglia infiltration, and axonal damage, which 
culminate in retinal ganglion cell (RGC) loss and reduced visual 
acuity (40, 43–45).
Recent studies have also discovered co-existing genetic 
changes in NF1-PA in addition to NF1 gene mutation, including 
heterozygous PTEN deletion and KIAA1549:BRAF duplication 
(46). Based on these observations, two Nf1 optic glioma GEM 
models were generated that additionally harbored either a 
heterozygous Pten deletion or KIAA1549:BRAF overexpres-
sion. While KIAA1549:BRAF overexpression did not provide 
an additional growth advantage, tumors from mice with a 
co-existing heterozygous Pten deletion had larger volumes, 
increased proliferation indices, and more microglia infiltration. 
TABLe 2 | Demographic and biological features of glioma cell lines.
Name Age Gender Histological  
subtype
Year made Mutations Primary 
PMiD Ref(s)
Other Refs 
(mutations 
only)
Note(s) Originating investigator/and 
institution or other source(s)
CHLA-03-AA 9 years F AA 25211508 Anat Erdreich-Epstein (Saban 
Research Institute, Children‘s 
Hospital Los Angeles); ATCC
IPNT-H 6 months M Hypothalamus PA Positive GFAP, A2B5, and CD44. Weakly positive 
vimentin
9428346 Dr. Geoffrey Pilkington (Institute 
of Psychiatry, London, UK)
NCH134 Adult DA 1996–2004 18398503 Dr. Christel Herold-Mende 
(Department of Neurosurgery, 
University of Heidelberg)
NCH480b Adult Oligoastrocytoma 1996–2004 18398503 Dr. Christel Herold-Mende 
(Department of Neurosurgery, 
University of Heidelberg)
NCH492 6 years Mix Nervous system; PA 1996–2004 Large copy number gain of chromosome arm 7q 
spanning the BRAF locus by array-CGH
18398503 Dr. Christel Herold-Mende 
(Department of Neurosurgery, 
University of Heidelberg; 
Sigma-Aldrich)
NCH514 Adult Oligoastrocytoma 1996–2004 18398503 Dr. Christel Herold-Mende 
(Department of Neurosurgery, 
University of Heidelberg)
Res186 PA Homozygous PTEN deletion at 10q23; 
active mTORC1/mTORC2; specific promoter 
hypermethylation TP73; high levels of phoso-Akt 
by WB; Phosphorylated GSK3β levels were low; S6 
activation, methylated GSTP1
19365568 24203892 Suppressed 
by MK8669 
(greater than 
Res259)
Dr. Michael Bobola (University of 
Washington, Seattle, WA, USA)
Res259 Pediatric DA PFGFRA gain, CDKN2A deletion; active mTORC1/
mTORC2; specific promoter hypermethylation 
FHIT, HIC1; Phosphorylated GSK3β levels were low 
by WB, high pS6 by WB
19365568 24203892 Dr. Michael Bobola University of 
Washington, Seattle, WA, USA
SF188 Pediatric GB 7% CD133 positive cells, disruption of p53 
pathway via point mutation TP53, RTK/PI3K/AKT 
pathway via NF1 deletion
Dr. Daphne Haas-Kogan  
(UCSF, San Francisco, CA, USA), 
UW479 Pediatric AA APC, CASP8, CD44, CDH13, CHFR, ESR1, 
GSTP1, IGSF4, MGMT, PAX5A, PAX6, RARB, 
methylated RASSF1A and TMS1, methylated 
GSTP1
19365568 Dr. Michael Bobola (University of 
Washington, Seattle, WA, USA)
AA, anaplastic astrocytoma; DA, diffuse astrocytoma; GBM, glioblastoma multiforme; HGG, high-grade glioma; PA, pilocytic astrocytoma; GB, glioblastoma, WT, wild type.
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TABLe 4 | Xenografts.
Name Histological subtype Mutation Reference (PMiD)
Subcutaneous BT-35 PA/AA WT BRAF 20806365
CB17SC-M scid−/− female mice with  
BT-40 tumor
PA/atypical teratoid malignant 
rhabdoid
Mutant [V600E] BRAF 20806365
TABLe 3 | Transgenic Mouse Models.
Name Penetrance, onset Histological subtype References 
(PMiD)
FMPC Differentiated neurons, embryonal 25246427
Nf1 (flox/mut); GFAP-Cre  
(FMC or Nf1+/–GFAPCKO)
100%, 2 months Differentiated neurons, embryonal; 
neuroglial
12077339 25772366 Used Cre/LoxP technology
Nf1 (flox/flox); GFAP-Cre Differentiated neurons 14695164 Poor breeders
Nf1 (flox/mut) Embryonal, Neurofibromin GFAP-Cre line 73.12 mice  
(Stock No. 012886)
Nf1 (flox/flox) Embryonal, Neurofibromin 11297510
Nf1+/– Embryonal, Neurofibromin 7920653 CCE-ES cells (45) 10f and 38a clones
Nf1+/–KRas 100%, 2 months Mixed embryonal and lung 
adenocarcinoma
11751630
Nf1+/–GFAP-mCKO 20%, 4 months Embryonal
NF1Syn1KO No tumor growth
6
Ricker et al. Research Roadmap for NF1-PA Therapeutic Discovery
Frontiers in Oncology | www.frontiersin.org December 2016 | Volume 6 | Article 259
Furthermore, inhibition of Nf1+/− non-neoplastic stromal 
cells (microglia) significantly decreases optic glioma growth 
and maintenance (47). These preclinical mouse models suggest 
that additional genetic changes in NF1-associated PA patients 
differentially influence tumor growth relevant to the design of 
future therapeutic strategies.
Xenografts and Cancer Stem Cells
Whereas xenografts of human tumors maintained in immu-
nocompromised mice have been regularly employed to predict 
the efficacy of candidate drugs, most of these xenografts derive 
from high-grade (malignant) cancers. In contrast, generating 
neoplastic cells from PA tumors has been challenging due to 
their low clonogenic nature and the requirement for a permissive 
tumor microenvironment. As presented in Table  4, only a few 
patient-derived xenograft (PDX) models of sporadic PA have 
been reported. Two such models, BT-35 and BT-40, have been 
used in a preclinical study of the selumetinib MEK inhibitor (48). 
BT-35 and BT-40 express WT and mutant BRAF (BRAFV600E; 
constitutively active BRAF), respectively. While BT-35 xenografts 
continued to grow in the presence of selumetinib, BT-40 xeno-
grafts are highly sensitive to MEK inhibition. To date, no PDX 
models exist for NF1-PA.
To develop robust human HGG PDX models, several groups 
have derived cancer stem cells (CSCs) as in  vitro and trans-
plantable in  vivo platforms for drug discovery and evaluation 
(49–51). Similar to their non-neoplastic counterparts, CSCs are 
capable of self-renewal and multilineage differentiation (52–54). 
Unfortunately, the CSCs generated from PA tumors have clo-
nogenic frequencies between 0.3 and 1.5% and often undergo 
oncogene-induced senescence (55). As such, no PA CSC models 
have been developed from human specimens.
Using GEM, the process of establishing and maintaining 
human NF1-PA CSC xenografts can be optimized. Using Nf1 
optic glioma GEM models, LGG CSCs have been isolated, 
which were capable of self-renewal, long-term passage, and 
multilineage differentiation (56). Importantly, these CSCs 
formed LGG-like lesions when injected into the brainstems of 
immunocompetent, but not immunocompromised (athymic), 
mice. This latter finding underscores the obligate role of the 
tumor microenvironment in Nf1 murine low-grade gliomagen-
esis. Further work using these CSCs may reveal the critical 
components of the tumor microenvironment required for 
CSC engraftment, which might be accurately recapitulated in 
rodents to enable xenografting of human NF1-PA tumors in 
the future.
POTeNTiAL DRUG TARGeTS
Molecular Signaling Pathways
Neurofibromin functions primarily as a suppressor of RAS 
and its downstream signaling pathways (Figure  2) (57–62). 
Neurofibromin contains a GAP (GTPase-activating protein)-
related domain (GRD) that accelerates the GTP hydrolysis of RAS, 
leading to RAS inactivation (63). PI3K/AKT and RAF/MEK/ERK 
are two common pathways downstream of RAS. Hyperactivation 
of the PI3K/AKT and MEK/ERK pathways are observed in Nf1-
deficient neural stem cells (NSCs) (64) and astrocytes (65). While 
each RAS effector pathway has different functions in NSCs rela-
tive to proliferation and glial differentiation, both the PI3K/AKT 
FiGURe 3 | Tumor microenvironment stimulates the growth of NF1-associated PA. Interactions between neoplastic cells (glioma cells and cancer stem cells) 
and non-neoplastic (stromal) cells are depicted. Stromal cells within the tumor environment include neurons, microglia, macrophages, and endothelial cells. Arrows 
indicate the paracrine factors (e.g., chemokines and growth factors) secreted by each cell type and their responsive cells.
FiGURe 2 | Neurofibromin is a negative regulator of RAS and its downstream effectors. Neurofibromin protein (2818 amino acids) contains a GAP-related 
domain (GRD) domain, which functions to inhibit RAS activity through accelerating RAS-GTP to RAS-GDP hydrolysis. The RAS downstream effector pathways are 
shown, including RAF/MEK/ERK, PI3K/AKT, and mTOR. Activation of these pathways increases cell growth and/or cell survival in Nf1-deficient neoplastic cells.
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and MEK/ERK pathways are hyperactivated in Nf1−/− astrocytes 
relative to their wild-type counterparts (62, 66–69). Importantly, 
these downstream effectors converge on the mTOR complex to 
regulate astrocyte growth in vitro and Nf1 optic glioma prolifera-
tion in vivo (9). Future laboratory investigations will be required 
to define the RAS effector signaling networks required for optic 
glioma maintenance relevant to adaptive and potential escape 
mechanisms from targeted therapies that might be operative in 
these tumors (56).
Tumor Microenvironment
Evidence from several different experimental studies has revealed 
a critical role for the tumor microenvironment in murine Nf1 optic 
glioma formation and growth. Similar to other LGG systems, the 
tumor microenvironment of Nf1 optic glioma consists of neoplas-
tic cells (glioma cells and CSCs) and non-neoplastic stromal cells 
(neurons, endothelial cells, and monocytes) (Figure 3). Increasing 
evidence suggests that neoplastic cells secrete paracrine factors 
(e.g., chemokines) to recruit stromal cells and stimulate growth 
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factor/cytokine production from these cells. The growth factors 
then interact with their cognate receptors on the cell surface of 
neoplastic cells to increase cell proliferation. The roles and inter-
actions of these cells within the microenvironment of NF1-PA 
remain to be completely elucidated. To date, the importance of 
microglia to PA pathogenesis is underscored by the finding that 
35–50% of the cells in these low-grade tumors are Iba1+ tissue 
macrophages (monocytes) (70). Monocytes in the brain can rep-
resent either resident tissue macrophages (microglia) that enter 
the brain during mid-embryonic development or peripheral 
macrophages from the bone marrow (71). In mouse Nf1 optic 
gliomas, the monocytes are Cd11b+, Cd45low, Cx3cr1+ microglia 
(70). These microglia are critical for gliomagenesis, such that 
impairing their directional migration into the tumor by genetic 
reduction of the Cx3cl1 receptor (Cx3cr1) delays optic glioma 
formation (72). Moreover, pharmacologic inhibition of microglia 
function with minocycline (73) or c-Jun-NH2-kinase (JNK) 
inhibitors (74) reduces optic glioma proliferation. In addition, 
genetic elimination of microglia using transgenic mice expressing 
the CD11b-thymidine kinase (TK) transgene results in dramatic 
reduction in optic glioma proliferation (70). Collectively, these 
observations establish that microglia in the tumor microenviron-
ment produce critical growth factors that increase optic glioma 
growth.
To identify potential growth factors elaborated by glioma-
associated microglia, RNA-sequencing of murine optic glioma-
associated microglia has revealed that the Ccl5 chemokine 
produced by tumor-associated microglia is a potent stromal fac-
tor important for optic glioma maintenance in mice (47). In this 
regard, Ccl5 was sufficient to increase Nf1-deficient astrocytes 
growth in vitro, and its inhibition using neutralizing antibodies 
reduced optic glioma proliferation in  vivo. Current studies are 
underway to identify additional chemokines and growth factors 
for potential stroma-directed glioma therapies.
visual Outcome
While 15–20% of NF1 patients develop OPGs, 30–50% will 
experience impaired visual acuity. Since surgery is rarely 
employed and radiation is associated with the development of 
secondary malignancy (75, 76), the standard of care entails the 
use of chemotherapy. One of the applications of mouse Nf1 optic 
glioma models is to define the mechanisms underlying tumor-
associated visual decline. As such, Nf1 optic glioma mice develop 
a time-dependent sequence of events, beginning with axonal 
injury at the tumor site, followed by axonal degeneration, RGC 
loss (apoptosis), retinal nerve fiber layer thinning, and reduced 
visual acuity (44, 77).
Neurofibromin plays critical roles in protecting neurons 
from degeneration and cell death. As such, RGCs harboring a 
germline Nf1 gene mutation (Nf1+/−) have smaller growth cone 
areas, shorter neurite lengths, and increased cell death compared 
to wild-type RGCs (78). These abnormal cellular phenotypes are 
due to impaired neurofibromin regulation of cyclic AMP (cAMP) 
generation. In these neurons, reduced neurofibromin expression 
results in lower cAMP levels, such that elevating cAMP levels 
using pharmacological methods increases the growth cone areas 
and neurite lengths of Nf1+/− RGCs in vitro. In addition, elevating 
cAMP levels greatly attenuates RGC cell death in Nf1 optic glioma 
mice in vivo (78). These observations raise the potential of future 
neuroprotective strategies aimed at reducing RGC death.
Current Pediatric NF1-LGG Clinical Trials
With respect to NF1-LGG, selumetinib, a MEK inhibitor that 
inhibits the growth of a BRAFV600E-expressing PA xenograft 
(48) and blocks growth in both Nf1 optic glioma (9) and 
KIAA1549:BRAF-driven NSC glioma (11) models, has been 
evaluated in a phase I clinical trial (http://clinicaltrials.org 
#NCT01089101) for pediatric LGG. Since the PI3K/AKT and 
MEK/ERK pathways converge on mTOR, treatments that target 
mTOR may still have utility. Several mTOR inhibitors other than 
sirolimus have been investigated for treating NF1- and sporadic 
LGG. Everolimus (RAD001), a rapamycin analog that targets 
mTOR, is currently being explored as a potential treatment in 
two separate trials (http://clinicaltrials.org #NCT01158651 and 
#NCT01734512, recruiting).
FUTURe MODeLS AND DeveLOPiNG 
New THeRAPeUTiC DRUGS
increase Biobanking and Database efforts
Especially relevant to NF1-LGG, proper communication and 
collaboration among patient families, clinicians, and research-
ers are highly recommended in order to preserve valuable LGG 
specimens for molecular characterization. The importance 
of donating tumor samples for research purposes should be 
emphasized to medical groups and families – especially for 
patients affected by NF1-PA, for which surgical biopsy samples 
are sometimes sparingly small. Legacy gifts of autopsy tumor tis-
sue and selfless donation can similarly propel the field forward, 
while simultaneously providing hope for families for whom 
treatments are not currently available. Most pediatric cancer 
families (93%) would agree to autopsies if given the option 
(79); however, there has been a decrease over the past several 
decades in the acquisition of autopsy specimens for research 
(79). Patients, advocates of patients, clinicians, and researchers 
should aim to spread awareness, enhance subject recruitment, 
and increase funding for the future storage of cryo-viable frozen 
tissue samples at one or multiple sites, with cataloging by way 
of a HIPAA-compliant online database such as the CTF NF1 
Registry.
expand the Spectrum of Nf1 GeM Models
While Nf1 mutant mouse models provide unprecedented oppor-
tunities for drug discovery and evaluation, the current collection 
of these strains does not fully capture the full spectrum of human 
clinical heterogeneity. Laboratory investigations have begun to 
identify the various factors that might underlie this inherent 
clinical heterogeneity. First, genotype–phenotype correlation 
studies in people with NF1 have revealed intriguing associations 
(80–84); the most striking of which is the finding that individuals 
with p1809 codon mutations do not develop dermal neurofibro-
mas (85). Relevant to brain tumors, NF1 patients with 5′ NF1 
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gene mutations have higher chance developing optic gliomas 
compared to patients with mutations at other locations of the 
NF1 gene (82). Based on these types of clinical observations, 
human iPSCs have been used to demonstrate that different NF1 
mutations lead to different levels of neurofibromin protein loss 
(39, 86, 87). These results suggest that not all NF1 gene mutations 
are equivalent.
To explore this further, GEM have recently been engineered 
to harbor specific Nf1 mutations seen in people with NF1. This 
is in contrast to the current Nf1 optic glioma mouse model in 
which the Nf1 gene is inactivated by the insertion of a neomycin 
targeting cassette, a genetic alteration not seen in individuals 
with NF1 (88, 89). Strikingly, in these proof-of-principle studies, 
Nf1 mice harboring a representative missense mutation did not 
develop optic gliomas, whereas those with a representative non-
sense mutation harbored optic gliomas with higher proliferative 
indices than the conventional Nf1 optic glioma strain (90). Future 
preclinical studies should be designed to incorporate mice with 
different germline Nf1 gene mutations and cooperating genetic 
changes (heterozygous Pten loss; KIAA1549:BRAF expression) as 
a way of more accurately representing the full spectrum of disease 
in this patient population.
Optimize Patient-Derived Xenograft 
Methodologies
As mentioned above, the growth of LGG PDXs likely requires 
trophic support from the tumor microenvironment. Current 
xenograft methodologies developed using HGG cells may not 
be suitable for generating LGG PDX due to the relative stromal 
independence of HGG cells. The methodologies for future PA 
PDX studies can be tested and optimized using xenografts devel-
oped from mouse NF1-LGG cells (56). Current mouse xenograft 
methodologies involve the isolation of single cells (CD133+) 
from the optic nerves of 3-month-old mice with NF1-LGG 
(Nf1+/−GFAPCKO mice) (56). The resulting glioma stem cells 
express several stem cell markers and a response to therapeutic 
treatments similar to that observed in humans. This model lays 
the groundwork for further investigation into potential PDXs.
SUMMARY
Since the discovery of the NF1 gene in 1990, great advances have 
been made to understand the cellular and molecular mechanisms 
underlying NF1-PA pathogenesis and maintenance. With the 
establishment of biobanking and registry initiatives, NF1-LGG 
specimens can be better characterized for actionable mutations. 
The resulting mutations and genomic alterations can next be 
evaluated in preclinical model systems as a means of identifying 
their contributions to tumor growth and targets for therapeutic 
intervention. Moreover, the incorporation of these cooperating 
genetic/genomic changes in combination with other factors, like 
the germline NF1 gene mutation, create a more representative 
spectrum of models that capture the innate clinical heterogeneity 
of these tumors for preclinical drug assessment and biomarker 
discovery. The implementation of these strategies offers the 
greatest opportunities to discover effective treatments for these 
common brain tumors, both for children with NF1 and those 
with non-syndromic LGG.
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